Skip to main content
BrainCited

Citicoline für Attention & Focus Difficulties

B

Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

<\/script>\n
`; }, get iframeSnippet() { const domain = 'braincited.com'; const params = 'ingredient\u003Dciticoline\u0026condition\u003Dattention\u002Dfocus'; return ``; }, get activeSnippet() { return this.method === 'script' ? this.scriptSnippet : this.iframeSnippet; }, copySnippet() { navigator.clipboard.writeText(this.activeSnippet).then(() => { this.copied = true; setTimeout(() => { this.copied = false; }, 2000); }); } }" @keydown.escape.window="open = false" @click.outside="open = false">

Embed This Widget

Style



      
      
    


    
    

      Widget powered by
      .
      Free, no account required.
    

  




    








    

        

            B

        

        

            
Fazit

            
            
Researchers reviewing 14 studies found established evidence for improvements in attention, processing speed, and working memory with citicoline supplementation, particularly in elderly populations with existing cognitive complaints.

            
            
        

    










    

  
Key Study Findings





    

        
        

            

                
                    Randomized Controlled Trial
                
                
                
                
                Double-blind
                
            

            
                Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.
            
            

                
                Dose: None
                
                
                vs.: placebo
                
                
                Outcome: ADHD symptom improvement
                
                
                Wirkung: None
                
                
                None
                
            

            
            
Population: pediatric patients aged 7-12 years diagnosed with ADHD

            
        

        
        

            

                
                    Other
                
                
                
                12 weeks
                
                
            

            
                Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.
            
            

                
                Dose: 19.17%
                
                
                vs.: None
                
                
                Outcome: cognitive function
                
                
                Wirkung: None
                
                
                None
                
            

            
            
Population: Covid-19 during the pandemic period between 2020 and 2022

            
        

        
        

            

                
                    Systematic Review
                
                
                n=8137
                
                
                
            

            
                Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.
            
            

                
                Dose: None
                
                
                vs.: None
                
                
                Outcome: Cocaine craving reduction
                
                
                Wirkung: None
                
                
                None
                
            

            
            
Population: Cocaine use disorder patients

            
        

        
        

            

                
                    Review
                
                
                
                
            

            
                Cholinergic nervous system and glaucoma: From basic science to clinical applications.
            
            

                
                Dose: None
                
                
                vs.: None
                
                
                Outcome: Mortality
                
                
                Wirkung: None
                
                
                None
                
            

            
            
Population: None

            
        

        
        

            

                
                    Review
                
                
                
                
            

            
                [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].
            
            

                
                Dose: None
                
                
                vs.: None
                
                
                Outcome: None
                
                
                Wirkung: None
                
                
                None
                
            

            
            
Population: None

            
        

        
    







    
    

        
        

            

  
Key Statistics





            


    

        
14

        
Studien

    

    

        
1600

        
Teilnehmer

    

    

        
            
            ↑
            
        
        
Positive

    

    

        B

        
Bewertung

    




        


        
        
        

            

  
Referenced Papers





            

                
                

                    

                        
                            Use of Citicoline in Attention-Deficit/Hyperactivity Disorder: A Pilot Study.
                        
                        
                            
                                RCT
                            
                            
                            
                        
                    

                    

                        Clinical neuropharmacology
                        None
                        
                        2 Zitierungen
                        
                    

                

                
                

                    

                        
                            Investigation of Cognitive Impairment in the Course of Post-COVID Syndrome.
                        
                        
                            
                                Other
                            
                            
                            
                        
                    

                    

                        Diagnostics (Basel, Switzerland)
                        2023
                        
                    

                

                
                

                    

                        
                            Pharmacological Treatments for Cocaine Craving: What Is the Way Forward? A Systematic Review.
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Brain sciences
                        2022
                        
                        17 Zitierungen
                        
                    

                

                
                

                    

                        
                            Cholinergic nervous system and glaucoma: From basic science to clinical applications.
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Progress in retinal …
                        2019
                        
                        107 Zitierungen
                        
                    

                

                
                

                    

                        
                            [X-chromosome-linked ichthyosis associated to epilepsy, hyperactivity, autism and mental retardation, due to the Xp22.31 microdeletion].
                        
                        
                            
                                Review
                            
                            
                            
                        
                    

                    

                        Revista de neurologia
                        2012
                        
                        12 Zitierungen
                        
                    

                

                
            

        

        

        
        
        

            

  
Dosage & Usage





            
mg = milligrams · mcg = micrograms (1,000× smaller) · IU = International Units


            
            

                
Übliche Dosierungen

                

                    
                    

                        
general:

                        
250-500 mg/day

                    

                    
                    

                        
cognitivesupport:

                        
500-2,000 mg/day

                    

                    
                

                
                

                    Obergrenze: Well-tolerated up to 4,000 mg/day in clinical trials
                

                
            

            

            
            

                
In der Forschung untersuchte Dosierungen

                

                    

                        
                            

                                Dosierung
                                Dauer
                                Wirkung
                                N
                            

                        
                        
                            
                            

                                None
                                --
                                
                                    
                                    Neutral
                                    
                                
                                --
                            

                            
                            

                                19.17%
                                12 weeks
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Mixed
                                    
                                
                                8137
                            

                            
                            

                                None
                                --
                                
                                    
                                    Positive
                                    
                                
                                --
                            

                            
                            

                                None
                                --
                                
                                    
                                    Mixed
                                    
                                
                                --
                            

                            
                        
                    

                

            

            

            
            

                Beste Einnahmezeit: Morning or split dose; can be taken with or without food
            

            
        

        

        
        
        

            

  
Safety & Side Effects





            

                
                

                    
Gemeldete Nebenwirkungen

                    
    
                        
                        
  • 
                            ⚠
                            Headache
                        
    • 
                        
                        
  • 
                            ⚠
                            Insomnia (if taken late in the day)
                        
    • 
                        
                        
  • 
                            ⚠
                            Mild gastrointestinal discomfort
                        
    • 
                        
                        
  • 
                            ⚠
                            Rare: restlessness or overstimulation
                        
    • 
                        
                    

                

                

                
                

                    
Bekannte Wechselwirkungen

                    
    
                        
                        
  • 
                            ●
                            Levodopa (may enhance dopaminergic effects)
                        
    • 
                        
                        
  • 
                            ●
                            Cholinergic drugs (additive acetylcholine increase)
                        
    • 
                        
                        
  • 
                            ●
                            Anticholinergics (may reduce citicoline effectiveness)
                        
    • 
                        
                    

                

                

                
                

                    

                        Tolerierbare Höchstaufnahmemenge: Well-tolerated up to 4,000 mg/day in clinical trials
                    

                

                
            

            

                Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.Konsultieren Sie immer Ihren Arzt, bevor Sie ein Nahrungsergänzungsmittel einnehmen.
            

        

        

        
        
        

            

  
Frequently Asked Questions





            




    
    

        
            Does Citicoline help with Attention & Focus Difficulties?
            
        
        

            Based on 14 studies with 1,600 participants, there is moderate evidence from clinical studies that Citicoline may support Attention & Focus Difficulties management. Our evidence grade is B (Good Evidence).
        

    

    
    

        
            How much Citicoline should I take for Attention & Focus Difficulties?
            
        
        

            Studies have used various dosages. A commonly studied range is 250-500 mg/day. Always consult your healthcare provider before starting any supplement regimen.
        

    

    
    

        
            Are there side effects of Citicoline?
            
        
        

            Reported side effects may include Headache, Insomnia (if taken late in the day), Mild gastrointestinal discomfort, Rare: restlessness or overstimulation. Most side effects are mild and dose-dependent. Consult your doctor if you experience any adverse reactions.
        

    

    
    

        
            How strong is the evidence for Citicoline and Attention & Focus Difficulties?
            
        
        

            We rate the evidence as Grade B (Good Evidence). This rating is based on 14 peer-reviewed studies with 1,600 total participants. The overall direction of effect is positive.
        

    

    




        

        

        
        
        

            

  
Related Evidence





            

                
                
                

                
                

                    
Citicoline für andere Beschwerden

                    

                        
                        
                            Memory Loss
                            B

                        
                        
                    

                

                
            

        

        

    


    
    












    

        FDA-Haftungsausschluss:
        Diese Aussagen wurden nicht von der Food and Drug Administration bewertet. Die Produkte und Informationen auf dieser Website sind nicht dazu bestimmt, Krankheiten zu diagnostizieren, zu behandeln, zu heilen oder zu verhindern. Die dargestellten Evidenzbewertungen basieren auf unserer Analyse veröffentlichter begutachteter Forschung und stellen keine medizinische Beratung dar. Konsultieren Sie immer Ihren Arzt, bevor Sie mit der Einnahme von Nahrungsergänzungsmitteln beginnen.